Display options
Cite
Hohlfeld R. Mesenchymal stem cells for multiple sclerosis: hype or hope?. Lancet Neurol. 2021;20(11):881-882doi: 10.1016/S1474-4422(21)00324-0.
Hohlfeld, R. (2021). Mesenchymal stem cells for multiple sclerosis: hype or hope?. The Lancet. Neurology, 20(11), 881-882. https://doi.org/10.1016/S1474-4422(21)00324-0
Hohlfeld, Reinhard. "Mesenchymal stem cells for multiple sclerosis: hype or hope?." The Lancet. Neurology vol. 20,11 (2021): 881-882. doi: https://doi.org/10.1016/S1474-4422(21)00324-0
Hohlfeld R. Mesenchymal stem cells for multiple sclerosis: hype or hope?. Lancet Neurol. 2021 Nov;20(11):881-882. doi: 10.1016/S1474-4422(21)00324-0. PMID: 34687621.
Copy Download .nbib Format: NLM
Share it on

Lancet Neurol. 2021 Nov;20(11):881-882. doi: 10.1016/S1474-4422(21)00324-0.

Mesenchymal stem cells for multiple sclerosis: hype or hope?.

The Lancet. Neurology

Reinhard Hohlfeld

Affiliations

  1. Institute of Clinical Neuroimmunology, University Hospital and Biomedical Centre, Faculty of Medicine, Ludwig Maximilians University Munich, Munich D-81377, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. Electronic address: [email protected].

PMID: 34687621 DOI: 10.1016/S1474-4422(21)00324-0

[No abstract available.]

Conflict of interest statement

RH declares no competing interests.

MeSH terms

Publication Types